Does cyt stock pay dividends?
Go Premium to see this Locked. Go Premium to see this Locked. Go Premium to see this CYT does not currently pay a dividend.
Is Cytec Industries (cyt) stock outpacing the S&P 500?
Cytec Industries has received 62.34% “outperform” votes from our community. MarketBeat's community ratings are surveys of what our community members think about Cytec Industries and other stocks. Vote “Outperform” if you believe CYT will outperform the S&P 500 over the long term.
Should you buy Cytec Industries (CBTI) stock?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytec Industries in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cytec Industries stock. View analyst ratings for Cytec Industries or view top-rated stocks.
What companies do other Cytec Industries investors own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cytec Industries investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Enviva Partners (EVA), QUALCOMM (QCOM), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX), Ampio Pha...
Should I buy or sell Cytec Industries stock right now?
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytec Industries in the last year. There are currently 5 buy rati...
What is Cytec Industries' stock price forecast for 2022?
5 analysts have issued 1 year price objectives for Cytec Industries' shares. Their forecasts range from $16.00 to $33.00. On average, they predict...
When is Cytec Industries' next earnings date?
Cytec Industries is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Cytec...
How were Cytec Industries' earnings last quarter?
Cytec Industries Inc (NYSE:CYT) announced its earnings results on Thursday, May, 5th. The specialty chemicals company reported ($0.40) EPS for the...
When did Cytec Industries' stock split? How did Cytec Industries' stock split work?
Cytec Industries shares split before market open on Thursday, September 18th 2014. The 2-1 split was announced on Thursday, July 17th 2014. The new...
Who are some of Cytec Industries' key competitors?
Some companies that are related to Cytec Industries include Sherwin-Williams (SHW) , Ecolab (ECL) , International Flavors & Fragrances (IFF) ,...
What other stocks do shareholders of Cytec Industries own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Cytec Industries investors own include Allena Pharmaceutic...
When did Cytec Industries IPO?
(CYT) raised $126 million in an initial public offering on Friday, June 18th 2021. The company issued 7,400,000 shares at $16.00-$18.00 per share....
What is Cytec Industries' stock symbol?
Cytec Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "CYT."
What is MarketBeat ratings?
What is Cytec Industries?
MarketBeat's community ratings are surveys of what our community members think about Cytec Industries and other stocks. Vote “Outperform” if you believe CYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYT will underperform the S&P 500 over the long term. You may vote once every thirty days.
What is the CYT symbol?
Cytec Industries Inc. is a global specialty materials and chemicals company focused on developing, manufacturing and selling value-added products. The Company offers aerospace and industrial materials, mining and plastics industries. The Company operates through four segments: Aerospace Materials, Industrial Materials, In Process Separation, and Additive Technologies. The Aerospace Materials segment includes advanced composites, carbon fiber, and structural film adhesives. The Industrial Materials segment includes structural composite materials, which serve automotive, motorsports, recreation, tooling, and other structural materials markets and process materials, which serves aerospace, wind energy, and other process materials markets. The In Process Separation segment includes mining chemicals and phosphines. The Additive Technologies segment includes polymer additives, specialty additives, and formulated resins. The Company operates as a wholly owned subsidiary of Solvay.
Does Cytec pay dividends?
Cytec Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "CYT."
When does the quiet period end for Cytec?
Cytec Industries does not currently pay a dividend.
What is Cyteir Therapeutics?
Cytec Industries' quiet period expires on Wednesday, July 28th. Cytec Industries had issued 7,400,000 shares in its public offering on June 18th. The total size of the offering was $133,200,000 based on an initial share price of $18.00.
Is Cyteir Therapeutics going public?
Cyteir Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing the next-generation of precision oncology medicines that inhibit deoxyribonucleic acid, or DNA, damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Synthetic lethality represents ...
What time do you trade in the pre market?
Cyteir Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
What is Cyteir Therapeutics?
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these sessions may offer less liquidity and inferior prices. Stock prices may also move more quickly in this environment.
Does market cap include convertible securities?
Cyteir Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing the next generation of precision oncology medicines that inhibit DNA damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. Its lead program, CYT-0851, as well as next-generation drug candidate CYT-1853, exploits a novel gain-of-function synthetically lethal relationship between overexpression of a fami
